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Pulmonary alveolar (phospholipo)proteinosis (PAP) is a rare lung disease, predominantly autoimmune in
nature. This case report describes a patient with insidious dyspnoea since 5years and a milky appearance
of her bronchoalveolar fluid, leading to the diagnosis of PAP. The onset of symptoms coincided with an
exchange of her silicone breast implants. Giant cell reaction in axillary adenopathies pointed towards
silicone leakage. Adjuvants, such as silicone, might boost pre-existing antigen reactions of the immune
system, potentially leading to autoimmune phenomena.
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Introduction
Pulmonary alveolar (phospholipo)proteinosis (PAP)
is a rare, diffuse lung disease characterised by the
abnormal accumulation of surfactant in the distal
air spaces. The disease was first described in 1958
by Rosen et al. There are three different forms of
PAP recognised: hereditary, secondary and the
acquired PAP. To date, the molecular pathogenesis
in over 90% of cases is elucidated. Disruption of
the GM-CSF (granulocyte macrophage-colony sti-
mulating factor) signalling, caused by a real or func-
tional deficiency of GM-CSF, avoids the terminal
differentiation of the alveolar macrophages. As a
result, clearance capacity for surfactant is disturbed
and surfactant will accumulate in the alveoli. This
leads to respiratory insufficiency while the lung archi-
tecture remains preserved.
Case Report
A 47-year-old woman was referred to our outpatient
clinic with a persistent, non-productive cough
since 5 years. Within the last few months, she also
developed dyspnoea, with decreased exercise tolerance
and fatigue. Now and then, she suffered from arthral-
gias and morning stiffness for about half an hour.
Besides a history of Raynaud’s phenomenon, there
were no other elements pointing to a connective
tissue disease. At the time of presentation, she was
still smoking. With the exception of this 15 pack-year
smoking history, no other significant exposures were
uncovered in her past medical history. She had a bilat-
eral silicon breast implantation 16 years ago, which
was revised and exchanged 10 years later for unknown
reason.
On physical examination, we noticed normal vital
signs and an oxygen saturation 94% while breathing
room air. Her lungs had bilateral fine crackles at the
bases. At the left anterior axillary fold, she had mark-
able palpable adenopathies.
Complete blood count did not show any irregulari-
ties. Inflammatory parameters and lactate dehydro-
genase level (LDH) were normal. Screening for
autoimmunity was negative and immunoglobulins
were normal.
Lung function tests revealed an isolated decreased
diffusing capacity (DLCO 40%).
High-resolution computed tomography (HRCT)
of the chest showed patchy ground-glass opacifica-
tion with interlobular septal thickening with a predo-
minantly central somewhat geographical distribution
(‘Crazy paving pattern’) (Figure 1).
A bronchoscopy was macroscopically normal.
Bronchoalveolar lavage (BAL), however, showed
turbid fluid and analysis revealed a decreased
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number of macrophages (75%; normal range 90–
100%). There was an increase in CD4- and CD8-
cell counts, with a CD4/CD8-ratio of 1.3.
PET-CT confirmed the presence of fluorodeoxy-
glucose-avid adenopathies at the left axilla. Excision
biopsy of these adenopathies showed on microscopic
evaluation a giant cell reaction of the foreign body
type with multiple fatty infiltrates and vacuoles, sug-
gestive of silicone leakage.
Consequently, the breast implants were excised.
Histology of the scar tissue also demonstrated the
presence of giant cells.
Discussion
The discrepancy between the mild clinical presentation
with insidious onset of dyspnoea and the important
radiographicfindings compatiblewith crazypavingpat-
tern, in combinationwith the findings onBALfluid (the
opaque and milky appearance of the bronchoalveolar
fluid with low macrophage counts, high CD4- and
CD8-counts), led to the diagnosis of PAP.
As mentioned in the Introduction section, there are
three different forms of PAP recognised: hereditary,
secondary and the acquired PAP.1 Acquired PAP is
also called autoimmune or idiopathic pulmonary
alveolar (phospholipo)proteinosis (iPAP) due to the
strong association with high levels of neutralising
GM-CSF autoantibodies, responsible for the patho-
genic cascade of surfactant accumulation. Although
not routinely tested for, these antibodies are known
as a highly sensitive and specific diagnostic tool for
autoimmune PAP.
Idiopathic pulmonary alveolar (phospholipo)pro-
teinosis represents the vast majority of cases (90%),
though the prevalence is estimated at only six to
seven individuals per million in the general popu-
lation. Acquired PAP typically presents at the age
of 30–50 years, with a male to female ratio of 2 : 1,
presumably caused by the association with smoking.
Silicone-based breast implants have been used
since the 1960s for both cosmetic augmentations
and reconstructive surgery. Since the beginning,
their local and systemic adverse effects remain of
great concern.
Around the implant, a fibrous capsule, rich in col-
lagen, is usually formed. Silicone leakage in and
through the fibrous envelope are well described
with progressing implant age (with or without rup-
ture of the implant). Once outside the capsule, the
silicone particles may disperse through soft tissue,
lymph nodes, or the vasculature to distant sites.2
Homolateral axillary localisations of silicone par-
ticles are frequently described, with comparable his-
tological findings to our case.2
Post-mortem analysis of 15 individuals with breast
implants, performed by Barnard et al., showed sig-
nificantly more silicone particles in the breast tissue,
lymph nodes and abdominal fat, in comparison to
individuals without breast implants. No significantly
different amounts of silicone particles were found in
the lungs, spleen and liver. As such, there are no
arguments for direct exposure of silicone to the
lungs.
The question has been raised whether this patient
has two co-incidental diagnoses or whether a corre-
lation between these two entities (iPAP and silicone
leakage) can explain the whole clinical picture.
The extensive literature concerning a correlation
between autoimmunity and silicone breast implants
demonstrates the controversy and the ongoing
debate. The inertia of the silicone particles has been
challenged.
Antisilicone antibodies
In different studies, higher levels of serum antisili-
cone antibodies were measured in implanted women
compared to almost none in non-implanted women. 3
Autoantibodies
After leakage of the silicones, contact with native
tissue may cause denaturation of tissue macromol-
ecules such as fibrinogen. The denatured molecules
may be recognised as foreign and as such triggering
the immune system in genetically susceptible persons.
The resulting autoantibodies may probably cross-
react with other substrates.2
Immunopathologic studies contradict each other in
light of possible evidence for higher prevalence of
Figure 1 Coronal reconstruction of high-resolution com-
puted tomography (HRCT) of the chest: patchy ground-
glass opacification with interlobular septal thickening with a
predominantly central somewhat geographical distribution
(‘Crazy paving pattern’).
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autoantibodies in implanted women than controls.
The difference in outcome is probably due to differ-
ent study designs, technical issues, patient
selection criteria or ascertainment bias.4 Moreover,
if the scientific evidence for a higher prevalence
of autoantibodies in implanted women would be
solid and sound, the clinical importance is not
yet clear
Well defined autoimmune disease
Hennekens et al. showed in a large cohort study,
based on self-reported symptoms of approximately
11 800 implanted women, a relative risk of 1.25
(95% CI: 1.08–1.41) for all defined connective tissue
diseases.4
In 2000, Janowsky et al. concluded in their meta-
analysis of 20 cohort, case–control and cross-sec-
tional publications that the risk was only 0.8 (95%
CI: 0.62–1.04) for defined connective tissue disease
following silicone breast implantation. The study of
Hennekens et al. was not included because they
used self-reporting of diseases.3,4
The potential higher risk of developing a well
defined connective tissue disease among silicone-
exposed individuals remains a point of discussion,
mentioning the same methodological pitfalls.
Undefined autoimmune disease
Shoenfeld et al. described ASIA, an autoimmune/
inflammatory syndrome induced by adjuvants. He
stated that adjuvants, such as silicone, boost pre-
existing antigen reactions of the immune system.
He linked this to aspecific symptoms like arthralgia,
fatigue, etc.4
Vasey et al. and Fryzek et al. reported statistically
significant increases in less specific symptoms like
arthralgia, fatigue and others after silicone-breast
implantation.4
A smaller, prospective study by Constant et al.
concluded that 1 year after breast implantation,
patients had more undefined complaints indicative
of underlying autoimmune disease, which were not
present before surgery.5
A relationship between silicone-breast implants
and yet non-defined autoimmune phenomena
seems plausible, although scientific evidence is still
lacking.
Conclusion
Our 47-year old patient presented with respiratory
and systemic complaints and a history of exchanged
silicone-breast implants.
Her clinical presentation, radiographic findings
and BAL fluid results matched the diagnosis of auto-
immune PAP. Silicone leakage led to a local inflam-
matory response, which was confirmed by
histological findings of foreign body reaction in the
axillary PET-avide lymph nodes. Raynaud’s
phenomenon, arthralgias and fatigue suggested an
autoimmune disease. Taken all together, a systemic
(auto)immunological response triggered by silicone
leakage could explain the whole clinical picture.
Review of the literature pinpointed some potential
pathways for generalised autoimmune responses after
silicone leakage. A (causal) relationship between sili-
cone implant and autoimmunity is still very doubtful.
Some evidence suggests a higher frequency of unde-
fined complaints probably indicative of underlying
autoimmune disease in implanted women. We
found no literature concerning the direct association
between silicone leakage and iPAP. Prospective, well
designed trials could at time lead to definitive
answers. Regarding the low frequency of the entity
iPAP in contrast to more frequent autoimmune dis-
eases, this could be a challenging task.
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